A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
← catalyst calendarNCT03833700 · readout in 224 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
70estimated
Sites
8
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-05 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Neoplasms
- Colorectal Neoplasms
- Gastrointestinal Tumors
Intervention
- Drug: E7386
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-limiting Toxicities (DLTs)
measured Baseline up to Cycle 1 (Cycle length is equal to [=] 28 days)
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 6 years)
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed